Leigh Ellis

The paper identifies population-associated differences in chromatin regulation in prostate cancer, linking reduced CTCF accessibility to aggressive tumor biology in Black men.

This study uses proteogenomics to identify ancestry-specific and shared molecular drivers in prostate cancer, revealing distinct biological programs and improving risk prediction.

This paper identifies the EZH2-TTP-mTORC1 axis as a driver of phenotypic plasticity and therapeutic vulnerability in prostate cancer, showing that combined inhibition of EZH2 and PI3K/mTORC1 improves anti-tumor activity.

This study identifies SOX2 and FOXA1 as a transcriptional partnership driving proliferation and lineage plasticity in therapy-resistant prostate cancer.

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

This study shows MYC overexpression disrupts AR transcriptional pause release, promoting aggressive prostate cancer progression.